Tradestie Institutional Equity Comparison Engine · Market Close Jan 07, 2026

AKRO vs FGEN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AKRO Captures Overall Composite Edge (60.0 BUY vs 61.2 BUY), While FGEN Leads 3–1 on Growth & Valuation Pillars

AKRO Overall Winner 6-Pillar Tally: AKRO 1 – 3 FGEN (2 Tie) Matrix Metrics: AKRO 5 – 5 FGEN

As of Jan 07, 2026, Akero Therapeutics, Inc. (AKRO) captures the overall head-to-head institutional edge over FibroGen, Inc (FGEN) on higher Unified Composite conviction (60.0/100 BUY vs. 61.2/100 BUY) after splitting the core matrix 5–5 (led by Profitability & Quality), while FGEN wins 3–1 across the 6-pillar growth and valuation breakdown. AKRO trades at $54.65 (N/M Forward P/E, 0.0% operating margin) versus FGEN at $9.71 (61.4x Forward P/E, -499.1% operating margin).

  • Composite vs. Pillar Nuance: While FGEN currently prints a higher short-term Unified Composite Score (61.2/100 BUY vs. AKRO 60.0/100 BUY), AKRO captures the overall institutional head-to-head verdict (5–5 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -499.1% operating margin) and revenue trajectory (+0.0% vs. +774.8% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AKRO vs FGEN
AKRO NASDAQ Head-to-Head Winner
Akero Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$54.65
+0.32% 1D
Market Cap $4.5B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.90β · 2% Vol
Unified Composite Score
60.0 / 100 BUY
Tech 55.0 Fund 52.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (7.8% over 20 days), RSI 67
RSI-14: 67.3 · SMA20: $54.36 · SMA50: $52.91
FGEN NASDAQ
FibroGen, Inc
Pharmaceutical Preparations
$9.71
+7.65% 1D
Market Cap $36.5M
TTM Revenue $8.3M
Forward P/E 61.4x
Beta / 30D Vol -20.79β · 102% Vol
Unified Composite Score
61.2 / 100 BUY
Tech 60.0 Fund 56.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 59
RSI-14: 59.2 · SMA20: $8.88 · SMA50: $9.26

6-Pillar Scorecard Institutional Category Breakdown (AKRO 1 – 3 FGEN)

Columns: Metric · AKRO · FGEN
1. Valuation Multiples FGEN
Forward P/E N/M 61.4x
Trailing P/E N/M 61.4x
PEG Ratio N/M N/M
EV / Revenue N/M 4.4x
2. Growth & Scale FGEN
Revenue Growth (YoY) +0.0% +774.8%
Earnings Growth (YoY) +0.0% +53.6%
TTM Revenue (USD) N/A $8.3M
Market Cap $4.5B $36.5M
3. Profitability & Quality AKRO
Gross Margin N/A N/A
Operating Margin 0.0% -499.1%
Net Profit Margin 0.0% 2598.9%
Return on Equity (ROE) -34.5% -1015.8%
4. Balance Sheet & Cash Flow FGEN
Cash Generation (TTM) N/A -$58M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $11.95 Book/Sh · -34.5% ROE -1015.8% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 7.3% (30th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Pharmaceutical Preparations Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AKRO (5) vs FGEN (5)
Institutional Metric AKRO FGEN Criterion Row Edge
Market Capitalization
Scale
$4.5B $36.5M Larger Scale AKRO
Trailing P/E Ratio
Valuation
N/M 61.4x Lower Multiple FGEN
Forward P/E Ratio
Valuation
N/M 61.4x Lower Multiple FGEN
Revenue Growth (YoY)
Growth
+0.0% +774.8% Higher Growth FGEN
Operating Margin (TTM)
Profitability
0.0% -499.1% Higher Margin AKRO
Net Profit Margin
Profitability
0.0% 2598.9% Higher Margin FGEN
Return on Equity (ROE)
Capital Efficiency
-34.5% -1015.8% Higher ROE AKRO
52-Week Range Position
Momentum
90% ($21–$58) 44% ($0–$22) Stronger Trend AKRO
Beta / 30D Volatility
Risk Regime
0.90β · 2% Vol -20.79β · 102% Vol Lower Realized Risk AKRO
Unified Institutional Score
Composite Signal
60.0 / 100 (BUY) 61.2 / 100 (BUY) Higher Composite FGEN
Trailing 12M Revenue (USD)
Operating Scale
N/A $8.3M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 4.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($11.95 Book/Sh · -34.5% ROE) -$58M EBITDA (-1015.8% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AKRO +25.37 pp
AKRO: +1.37% · FGEN: -24.0%
3M Horizon AKRO +49.66 pp
AKRO: +22.48% · FGEN: -27.18%
6M Horizon FGEN +2516.7 pp
AKRO: -0.11% · FGEN: +2516.59%
1Y Horizon AKRO +132.25 pp
AKRO: +93.52% · FGEN: -38.73%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AKRO vs FGEN. Trailing 12-month operating profitability (AKRO 0.0% vs FGEN -499.1%) and valuation multiples (AKRO N/M vs FGEN 61.4x Forward P/E) are benchmarked directly in Pillar 4 below.

AKRO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-34.5% · N/M
FGEN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$8.3M
Gross MarginN/A
Op. Margin-499.1%
ROE / Fwd P/E-1015.8% · 61.4x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AKRO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 7.3%
IV Percentile 30th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact AKRO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
FGEN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact FGEN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AKRO Moat Profile Cyclical / Execution-Driven Positioning
Pharmaceutical Preparations Operator
Competes within the Pharmaceutical Preparations value chain with $4.5B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
FGEN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $36.5M market capitalization and -499.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ AKRO vs FGEN Key Questions & Quantitative Answers

As of Jan 07, 2026, Akero Therapeutics, Inc. (AKRO) captures the overall head-to-head institutional edge over FibroGen, Inc (FGEN) on higher Unified Composite conviction (60.0/100 BUY vs. 61.2/100 BUY) after splitting the core matrix 5–5 (led by Profitability & Quality), while FGEN wins 3–1 across the 6-pillar growth and valuation breakdown. AKRO trades at $54.65 (N/M Forward P/E, 0.0% operating margin) versus FGEN at $9.71 (61.4x Forward P/E, -499.1% operating margin). Composite vs. Pillar Nuance: While FGEN currently prints a higher short-term Unified Composite Score (61.2/100 BUY vs. AKRO 60.0/100 BUY), AKRO captures the overall institutional head-to-head verdict (5–5 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -499.1% operating margin) and revenue trajectory (+0.0% vs. +774.8% YoY).

FGEN leads the Growth & Scale pillar: AKRO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with FGEN at +774.8% YoY revenue growth and +53.6% YoY earnings growth on $8.3M TTM revenue (N/A gross margin, -499.1% operating margin). On trailing 12-month operating scale, AKRO generates N/A in USD-normalized revenue versus $8.3M for FGEN. In operating R&D and SG&A reinvestment, AKRO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for FGEN.

FGEN screens cheaper on headline valuation multiples. AKRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas FGEN trades at 61.4x Forward P/E, 61.4x Trailing P/E, N/M PEG, and 4.4x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AKRO (-34.5% ROE) versus FGEN (-1015.8% ROE) capital efficiency.

In options market volatility and institutional positioning, AKRO carries 7.3% implied volatility (30th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.90β · 2% Vol realized risk). By comparison, FGEN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-20.79β · 102% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Jan 07, 2026. For educational research only; not investment advice.